Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Do Practice and Experience Maketh the Marketer?
June 27, 2011
- Korosho to Promptly Assess Bladder Cancer Risk due to Actos
June 27, 2011
- Dacogen Increases OS in AML Patients: Eisai
June 27, 2011
- Aratani Family Excluded from Teva-Controlled Taiyo
June 27, 2011
- Novartis, Ono to Promote Rivastigmine Stressing Its Beneficial Effects on ADL
June 27, 2011
- All Clinical Studies Need to Be Conducted According to Global Standards: Expert Committee
June 27, 2011
- Lenvatinib Shows ORR of 59% in Global PII: Eisai
June 27, 2011
- Merck to License Biosimilar of Enbrel from Hanwha of South Korea
June 27, 2011
- Daiichi Sankyo Confident about Independently Expanding Share for Memary
June 27, 2011
- Korosho to Enhance Generics' Reliability: Minister Hosokawa
June 27, 2011
- PIII Study Confirms Safety, Efficacy of Rotigotine Patch: Otsuka
June 27, 2011
- Mr Yoshida Points Out Need to Review NHI Pricing Rules for Generics
June 27, 2011
- Janssen, Takeda to Expand Share of Reminyl through Comarketing
June 27, 2011
- JACDS Draws Up GL for Power Saving This Summer
June 27, 2011
- TS-1 Non-Inferior to Gemcitabine in Pancreatic Cancer: Taiho
June 27, 2011
- Study Group to Discuss System for Relieving Victims of Health Damage Due to Anticancer Drugs
June 27, 2011
- Combined Sales of 24 Drug Makers Show Zero Growth
June 27, 2011
- FDA Approves Ciclesonide in Alternative HFA for Rhinitis: DSP
June 27, 2011
- Sanofi: Lyxumia Plus Insulin Shows Promise in PIII Study
June 27, 2011
- Korosho Council Approves Draft Report on Measures against Rheumatism, Allergy
June 27, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…